TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03675217

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PE
Description: Physical exercise program for familiy caregivers. 36 session physical exercise (3 sessions/week) performed by physioterapist. It incluided exercices to improve coordination, aerobic capacity, control motor and strenght

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Usual Care
Description: Usual Programe in primary care for family caregivers. 4 session (2 session/week). It incluides: ergonomy, postural hygiene, mobilitation of patients and self-care.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Usual Programe in primary care for family caregivers. 4 session (2 session/week). It incluides: ergonomy, postural hygiene, mobilitation of patients and self-care.
Study: NCT03365180

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Starter Kit Algorithm
Description: Long acting insulin titration to target
Study: NCT00318695

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotics
Description: Bifidobacterium longum \[BL999\] and Lactobacillus rhamnosus \[LPR\]

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Commercially available cow's milk based infant formula without probiotic supplementation
Study: NCT01940822

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Energy Drink

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Energy Drink

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo Drink

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo Drink
Study: NCT03713099

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Microwave ablation
Description: Microwave ablations will be performed under general anesthesia via a transbronchial approach by an interventional pulmonologist or thoracic surgeon. Prior to the ablation, the treating physician will perform an endobronchial ultrasound (EBUS) to confirm disease staging.
Study: NCT02327234

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ibuprofen
Description: 2x 200mg ibuprofen, single dose, blinded in 00 capsules

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: lactose filled 00 capsules to match appearance of ibuprofen intervention
Study: NCT06233708

Intervention type: DRUG
Intervention: Non-Selective Beta-Adrenoreceptor Agonists for Systemic Use
Description: Non-selective blocker including Propranolol, Carvedilol PO was prescribed
Study: NCT03099525

Intervention type: OTHER
Intervention: ILD
Description: This is an observational study without any intervention.

Intervention type: OTHER
Intervention: ILD
Description: This is an observational study without any intervention.
Study: NCT01932385

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Best Supportive Care

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Best Supportive Care
Study: NCT00133796

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Herceptin
Description: IV
Study: NCT01380366

Intervention type: DRUG
Group type: OTHER
Intervention: Somatropin
Description: Patients are given somatropin (growth hormone) for their short bowel syndrome for 28 days at a dose of 0.1 mg/kg subcutaneously daily to a maximum of 8 mg daily.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Seven Day Food Diary
Description: Subjects are asked to fill out a seven day food diary the week prior to their inpatient appointment, prior to receiving rHGH treatment for their short bowel syndrome. Subjects will be asked to repeat the use of a food diary after completing the administration of the growth hormone.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Blood Tests (standard of care)
Description: Blood tests are taken (standard of care) to evaluate the potential hepato-protective effects of improving intestinal barrier function on those receiving human growth hormone for short bowel syndrome. Per clinical protocol to test liver function i.e. Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), Alkaline phosphatase (ALP), Gamma-glutamyl transpeptidase (GGT), Total Bilirubin). A complete blood count (CBC) with platelets (PLTS) and white-count differential (WBC with diff) is performed to check for anemia and infection. These tests will be taken at baseline (before fasting) and repeated again on the 28th day (last dose) of the growth hormone. Blood is also taken at clinical visit over the next two years (approximately every two months).

Intervention type: OTHER
Group type: OTHER
Intervention: Fasting
Description: Eight hour overnight fast prior to being given sucralose, mannitol, lactulose, and sucrose. This is done at baseline (day one) and repeated again after the last dose of growth hormone and prior to sugar permeability urine tests.

Intervention type: OTHER
Group type: OTHER
Intervention: Sugar Permeability Test
Description: Subject will be given 4 capsules of sucralose (250mg per capsule), 2.0 grams of mannitol, 7.5 grams of lactulose, and 40 grams of sucrose in 150 mL of water. This will be given on the second day of the study after an 8-hour overnight fast and repeated within 72 hours of the last dose of growth hormone.

Intervention type: OTHER
Group type: OTHER
Intervention: Urine Collection
Description: Urine will be collected for the following five hours after subject has been given combination of sucralose, mannitol, lactulose, and sucrose to complete the intestinal sugar permeability test looking at urine ratio of lactulose to mannitol (L/M ratio). Tests include urinalysis (UA) and a blood urea nitrogen (BUN)/creatinine (Cr).
Study: NCT01019993

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: conventional OLV followed with IL-HFPPV
Description: The patients' lungs were mechanically ventilated with intermittent positive pressure ventilation using fraction of inspired oxygen (FiO2) of 0.5 in air, tidal volume (VT) of 8 mL/kg, inspiratory to expiratory \[I: E\] ratio of 1:2.5, zero positive end-expiratory pressure (PEEP), respiratory rate (R.R) was adjusted to achieve an arterial carbon dioxide tension (PaCO2) 35-45 mm Hg and peak inspiratory pressures were limited to 35 cm H2O. After pleurotomy, OLV was initiated with the same ventilatory settings for the dependent lung. After 30 min, the non-dependent collapsed lung was ventilated using HFPPV mode (IL-HFPPV) with another identical ventilator, with an internal circuit of low compliance, using FiO2 of 0.5 in air, VT 3 mL/kg, I: E ratio \<0.3 and R.R 60 breaths/min.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: conventional OLV followed with IL-HFPPV
Description: The patients' lungs were mechanically ventilated with intermittent positive pressure ventilation using fraction of inspired oxygen (FiO2) of 0.5 in air, tidal volume (VT) of 8 mL/kg, inspiratory to expiratory \[I: E\] ratio of 1:2.5, zero positive end-expiratory pressure (PEEP), respiratory rate (R.R) was adjusted to achieve an arterial carbon dioxide tension (PaCO2) 35-45 mm Hg and peak inspiratory pressures were limited to 35 cm H2O. After pleurotomy, OLV was initiated with the same ventilatory settings for the dependent lung. After 30 min, the non-dependent collapsed lung was ventilated using HFPPV mode (IL-HFPPV) with another identical ventilator, with an internal circuit of low compliance, using FiO2 of 0.5 in air, VT 3 mL/kg, I: E ratio \<0.3 and R.R 60 breaths/min.
Study: NCT03444207

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Endurance training
Description: The women in group A underwent endurance exercise on cycle ergometers (Schwinn Evolution, Schwinn Bicycle Company, Boulder, Colorado, USA). Exercise sessions consisted of a five-minute warm-up (stretching exercise) at low intensity (50%-60% of maximum heart rate), a 45-minute exercise (at 50%-80% of maximum heart rate), five minutes of cycling without a load, and five minutes of closing stretching and breathing exercise of low intensity.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Endurance-strength training
Description: Group B performed endurance-strength exercise consisting of a five-minute warm-up (stretching exercises) of low intensity (50%-60% of maximum heart rate), a strength component, an endurance component, 5 minutes cycling without a load, and a 5 minutes closing stretching and breathing exercise of low intensity. The 20-minute-long strength component was performed using a neck barbell and a gymnastic ball. Directly after the strength exercise, the women took part in a 25-minute endurance exercise on cycle ergometers (Schwinn Evolution, Schwinn Bicycle Company, Boulder, Colorado, USA) at 50%-80% of maximum heart rate.
Study: NCT00774475

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: comparison of different dosage of clopidogrel
Description: clopidogrel 75 mg/day versus clopidogrel 150 mg/day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: doubled therapy
Description: clopidogrel 150 mg/day
Study: NCT03641027

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Increased physical activity
Description: Preoperatively~Individual coaching by a physical therapist to:~* increase physical activity 30 minutes/day (At least 150 min/week)~* decrease time spent sitting/lying~Telephone follow up one week after the intervention starts~At the hospital~-Frequent mobilization~After discharge~A telephone follow up one week postoperatively with coaching by a physical therapist to:~* increase physical activity 30 minutes/day (At least 150 min/week) until 8 weeks postoperatively~* decrease time spent sitting/lying~The intervention includes a prescribed FaR (Fysisk aktivitet på recept) with frequency, duration and intensity of the activity corresponding 12-15 on the BORG-RPE scale.

Intervention type: OTHER
Group type: OTHER
Intervention: Standard care
Study: NCT04264741

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: repetitive transcranial magnetic stimulation (rTMS)
Description: The iTBS group received 900 pulses per day: 3-pulse 50-Hz bursts given every 200 ms (at 5 Hz), 2 s on and 8 s off for 5 min, at 100% resting motor threshold (rMT), over the left DLPFC (F3, EEG system) (4 weeks, 20 daily sessions). A figure-8-shaped Cool-B70 stimulation coil from MagPro X100 device (MagVenture, Farum, Denmark) was used for accurately targeted stimulation. Motor threshold was determined over the left motor cortex, by finding the lowest intensity that produced a motor response in the right abductor pollicis brevis muscles (APB), which produced five motor-evoked potentials responses of at least 50 mV in 10 trials.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham repetitive transcranial magnetic stimulation (rTMS)
Description: The iTBS group received 900 pulses per day: 3-pulse 50-Hz bursts given every 200 ms (at 5 Hz), 2 s on and 8 s off for 5 min, at 100% resting motor threshold (rMT), over the left DLPFC (F3, EEG system) (4 weeks, 20 daily sessions). A figure-8-shaped sham Cool-B70 stimulation coil from MagPro X100 device (MagVenture, Farum, Denmark) was used for accurately targeted stimulation. Motor threshold was determined over the left motor cortex, by finding the lowest intensity that produced a motor response in the right abductor pollicis brevis muscles (APB), which produced five motor-evoked potentials responses of at least 50 mV in 10 trials.
Study: NCT02679976

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: etafilcon A
Description: Marketed Multifocal Contact Lens
Study: NCT03603613

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: YRI
Description: The YRI is designed to assist youth facing complex problems using evidence-based treatments that have been tested and shown to work well in other settings and cultures. The YRI has three specific goals: 1) develop emotion regulation skills for healthy coping; 2) develop problem-solving skills to assist with achieving goals, and; 3) improve interpersonal skills to enable healthy relationships and effective communication. It integrates six CBT-based, empirically-supported practice elements shown to have transdiagnostic efficacy across disorders ranging from major depressive disorder to PTSD and conduct disorders. The YRI's six evidence-based components are delivered in three phases common in trauma-informed interventions: stabilization, integration, and connection.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: EPP
Description: The youth capacity development component of GIZ's EPP includes the following core components: financial literacy, entrepreneurship, and vocational training delivered through six modules (agro-processing, solar photovoltaic installation and maintenance, governance and conflict resolution, psychosocial competencies, entrepreneurship, employability). Youth will be trained at training sites and have access to a youth center in the area. These centers will have agricultural equipment and machinery available for youth to use. Our YRI curriculum will be used for the psychosocial competency training module.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: EPP
Description: The youth capacity development component of GIZ's EPP includes the following core components: financial literacy, entrepreneurship, and vocational training delivered through six modules (agro-processing, solar photovoltaic installation and maintenance, governance and conflict resolution, psychosocial competencies, entrepreneurship, employability). Youth will be trained at training sites and have access to a youth center in the area. These centers will have agricultural equipment and machinery available for youth to use. Our YRI curriculum will be used for the psychosocial competency training module.
Study: NCT04009837

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Hip-focused rehabilitation intervention
Description: The hip-focused intervention includes a blend of hip-focused rehabilitative techniques and some basic lumbar spine-directed techniques. The hip-focused arm includes tailored manual therapy, progressive strengthening exercises, and flexibility exercises for the hip, as well as spinal flexibility and trunk muscle training exercises. The intervention will be delivered by licensed physical therapists in one-hour sessions, twice per week, for 8 weeks.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Spine-focused rehabilitation intervention
Description: The spine-focused rehabilitation intervention is a direct and comprehensive lumbar spine rehabilitative program, but it does not include hip treatment. The spine-focused arm includes spinal manual therapy, spinal flexibility exercises, and trunk muscle training exercises. The intervention will be delivered by licensed physical therapists in one-hour sessions, twice per week, for 8 weeks.
Study: NCT01244464

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IMOVAX Polio™-Inactivated types 1, 2, and 3 poliovirus D vaccine
Description: 0.5 mL, at 2, 3, and 4 months; Intramuscular
Study: NCT04270188

Intervention type: OTHER
Intervention: evolution of patient symptoms
Description: evolution of symptoms on the PGI-I scale (score 1, 2, or 3) 2 months after surgery
Study: NCT01553851

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1120212
Description: Trametinib (GSK1120212) is a selective MEK1 and MEK2 inhibitor with selective activity towards BRAF and RAS mutant cancer cell lines and hematopoietic cancer cells from AML and CML origins.
Study: NCT00205166

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cardiac SPECT imaging Rest and Stress
Description: adenosine perfusion scintigraphy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cardiac SPECT imaging Rest and Stress
Description: adenosine perfusion scintigraphy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Caffeine
Description: Caffeine 400 mg po

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Caffeine
Description: Caffeine 200 mg po
Study: NCT01075776

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: C-type natriuretic peptide (CNP)
Description: 360 pmol/min for 15 minutes intra-arterially

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Sodium Chloride 0.9% intra-arterially 0.5ml/min

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetylcholine
Description: 2 stepped infusions for a total 9min per limb, totalling 1.05micromoles per limb

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Acetylcholine
Description: 2 stepped infusions for a total 9min per limb, totalling 1.05micromoles per limb
Study: NCT02366871

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral apixaban
Description: To evaluate the incidence of major bleeding (including CRNM bleeding) events in women undergoing surgery for gynecologic cancer with apixaban 2.5 mg BID compared to current standard of care, subcutaneous enoxaparin 40 mg QD for 28 days post surgery.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Subcutaneous enoxaparin
Description: To evaluate the incidence of major bleeding (including CRNM bleeding) events in women undergoing surgery for gynecologic cancer with apixaban 2.5 mg BID compared to current standard of care, subcutaneous enoxaparin 40 mg QD for 28 days post surgery.
Study: NCT03607318

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: iASIST
Description: Integrated Alcohol and Suicide Intervention for Suicidal Teens

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: iASIST
Description: Integrated Alcohol and Suicide Intervention for Suicidal Teens
Study: NCT01838876

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cariprazine
Description: Cariprazine capsules 0.5 mg, 1.0 mg, and 1.5 mg; Cariprazine doses 1.5, 3.0, or 4.5 mg/day (d); patients will be titrated to a starting dose of 3.0 mg/d. Patients can stay on 3.0 mg/d or the dose can be adjusted to 1.5 mg or 4.5 mg based on investigator's judgment of response and tolerability. Oral administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antidepressant Therapy (ADT)
Description: ADT such as citalopram, escitalopram, fluoxetine, sertraline, paroxetine, vilazodone, venlafaxine, desvenlafaxine, duloxetine or bupropion prescribed in accordance with its respective FDA approved package insert for each drug
Study: NCT01882452

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Memory Specificity Training
Description: This intervention is a manualised, structured treatment delivered over 5 x 60 minute sessions to groups of 5-8 individuals. This treatment involves repeated practice of retrieving specific autobiographical memories in response to positive, negative and neutral cue words. There is a single psychoeducation component in the first session about memory difficulties common in depression which provides the rationale for this treatment. The training is supplemented by weekly homework practice.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Education and Support
Description: The education-and-support comparison condition is matched with the experimental arm for length and format (ie., 5 x 60 minute weekly sessions in groups of 5-8 individuals). Groups receive a single psychoeducation component where information about depression is provided. This is followed by non-directive support where participants are encouraged to raise different kinds of events that occur each week for discussion in the group. The sessions are supplemented by a homework diary where participants will be invited to note down an event that occurs each day, which may be positive, negative, or benign and non-emotional in nature. This material will provide the basis for discussion in the weekly group meetings.
Study: NCT00580320

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dacarbazine and bortezomib
Description: Level 0: Dacarbazine 190 mg/m2 + Bortezomib 1.0 mg/m2; Level 1: Dacarbazine 250 mg/m2 + Bortezomib 1.0 mg/m2; Level 2: Dacarbazine 250 mg/m2 + Bortezomib 1.3 mg/m2; Level 3: Dacarbazine 250 mg/m2 + Bortezomib 1.6 mg/m2; Level 4: Dacarbazine 330 mg/m2 + Bortezomib 1.6 mg/m2; Level 5: Dacarbazine 440 mg/m2 + Bortezomib 1.6 mg/m2; Level 6: Dacarbazine 580 mg/m2 + Bortezomib 1.6 mg/m2
Study: NCT02935920

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Individualized, tailored follow-up program
Description: Individualized follow-up in the context of shared decision making, with the use of PRO-data to evaluate the patient needs of consultations.
Study: NCT00325637

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cilnidipine
Description: Cilnidipine 10\~20mg, qd, po for 4 weeks.
Study: NCT03980678

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Mineral Rich Algae
Description: Lithothamnion species is rich in calcium, magnesium (Mg) and 72 other trace elements absorbed from sea-water during the organisms life. Mineral-rich 'fronds' break off from the living organism, fall to the ocean floor and are harvested (AquaminF). The mineral extract in soluble form contains \~13.1% Calcium, \~1.04% Magnesium and measurable levels of 72 other trace minerals. Following or prior to a washout period (crossover intervention), participants will consume the Aquamin Soluble equivalent of 1000mg Calcium in 250 ml of orange flavored water for a 7 day loading period.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Orange flavoured water with maltodextrin as the placebo
Description: Following or prior to a washout period (crossover intervention), participants will consume 250 ml of orange flavoured water (containing 20mg of Calcium with maltodextrin) for a 7 day period.
Study: NCT01545336

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anastrozole
Description: 1 mg tablet to be taken 1 time daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 mg tablet to be taken 1 time daily
Study: NCT00956202

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Swine A/H1N1 influenza vaccine (split virion, inactivated)
Description: 0.5 mL, Intramuscular on Day 0 and Day 21 (all participants); and 0.5 mL of a trivalent influenza vaccine (TIV) at Month 13 (antibody persistence subset)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Swine A/H1N1 influenza vaccine (split virion, inactivated + Adjuvant)
Description: 0.5 mL, Intramuscular on Day 0 and Day 21 (all participants); and 0.5 mL of a trivalent influenza vaccine (TIV) at Month 13 (antibody persistence subset).
Study: NCT00657020

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo lozenge
Study: NCT00956202

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Swine A/H1N1 influenza vaccine (split virion, inactivated + Adjuvant)
Description: 0.5 mL, Intramuscular on Day 0 and day 21